A New Digital Value Chain Model with PLC in Biopharmaceutical Industry: The Implication for Open Innovation

ABSTRACT: The advancement of technology in the biopharmaceutical industry has spearheaded the speed and scale of digitalization in various aspects. New drug development is becoming more complex, costly, and challenging. This paper examines how the pharmaceutical value chain model could integrate wit...

Full description

Bibliographic Details
Main Authors: YongChan Kim, Erdal Atukeren, YeonWoo Lee
Format: Article
Language:English
Published: Elsevier 2022-06-01
Series:Journal of Open Innovation: Technology, Market and Complexity
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S219985312200004X
Description
Summary:ABSTRACT: The advancement of technology in the biopharmaceutical industry has spearheaded the speed and scale of digitalization in various aspects. New drug development is becoming more complex, costly, and challenging. This paper examines how the pharmaceutical value chain model could integrate with the product-life-cycle perspective to better explain the drug development process changes and how the digital transformation could be implemented at each stage of the drug development process. We suggest a new framework to capture digital value creation in the biopharmaceutical industry by focusing on the specific processes in new drug development and integrating the product life cycle management and value chain model. The new framework has operational implications for the biopharmaceutical industry, where digital transformation can simplify and increase the efficiency in each phase, from drug discovery, clinical trials, regulatory, manufacturing, commercialization, to monitoring processes.
ISSN:2199-8531